Recent 8-K filings for COCP
Highest-materiality recent filing
Cocrystal Pharma Q3 net loss $4.9M; cash $13M; expects topline data from two studies soon
- Net loss Q3 2024 of $4.9M ($0.49 per share) vs $4.2M ($0.41) in Q3 2023 which included $1.6M legal settlement.
- Cash and cash equivalents $13.0M as of Sep 30, 2024, down from $26.4M at Dec 31, 2023; working capital $12.3M.
-
Cocrystal Pharma appoints James Sapirstein as CEO, replacing co-CEOs Sam Lee and Jim Martin
James Sapirstein appointed CEO effective June 3, 2026, replacing Sam Lee and Jim Martin as co-CEOs.
-
Cocrystal Pharma announces discovery of pan-viral inhibitors with <50 nM potency against hantavirus
Novel pan-viral inhibitors target L-protein of Andes hantavirus; IC50 <50 nM against hantaan virus in vitro.
-
CDI-988 mechanism and Phase 1b human challenge study featured at ICAR 2026 in Prague.
-
Cocrystal Pharma receives FDA Fast Track designation for norovirus antiviral CDI-988
FDA granted Fast Track designation for oral, direct-acting protease inhibitor CDI-988 for norovirus.
-
Net loss $8.8M ($0.78/sh) vs $17.5M ($1.72/sh) in 2024; R&D spend down to $5.1M from $12.5M.
-
Cocrystal Pharma board member Dr. Anthony Japour passes away on March 10, 2026
Dr. Anthony Japour, a member of Cocrystal Pharma's board of directors, died on March 10, 2026.
-
Cocrystal Pharma doses first subjects in Phase 1b norovirus challenge study for CDI-988
First subjects dosed in Phase 1b challenge study (NCT07198139) at Emory University evaluating CDI-988 for norovirus prevention and treatment.
-
Cocrystal Pharma's CDI-988 oral norovirus inhibitor to be featured at ICAR 2026
CDI-988 is the first oral antiviral drug candidate developed for prevention and treatment of norovirus infections.
-
Cocrystal Pharma grants stock options to directors, officers, and consultant under 2025 Plan
Non-qualified stock options granted to 7 directors, 2 executive officers, and 1 consultant, vesting over 1-2 years.
-
IRB approval from Emory University to initiate Phase 1b human challenge study with CDI-988 for norovirus prevention and treatment.
-
Cocrystal Pharma to present at NobleCon 21 on Dec 3, 2025
CFO/co-CEO James Martin to give Company overview and clinical progress update.
-
Cocrystal Pharma Reports Q3 2025 Net Loss of $2.0M, Provides Norovirus and Influenza Program Updates
Received FDA IND clearance for CDI-988 as norovirus preventive and treatment; Phase 1b challenge study expected to begin Q1 2026.
-
Cocrystal Pharma raises $1.03M in private placement with four insider investors at $1.39/unit
Sold 739,426 units (1 share + 2 warrants) at $1.39/unit for $1.03M to four accredited insider purchasers.
-
Cocrystal Pharma receives ~$500K NIH SBIR award for influenza antiviral program
Award from NIH/NIAID to support development of novel oral broad-spectrum antiviral for influenza A and B.
-
Cocrystal Pharma closes $4.7M registered direct offering with warrant coverage
Gross proceeds of ~$4.75M from sale of 2,764,710 shares at $1.70 each.
-
Cocrystal Pharma announces up to $13M registered direct offering at $1.70/share
$4.7M upfront from sale of 2,764,710 shares at $1.70; closing expected Sep 15, 2025.
-
President/co-CEO Sam Lee presented CDI-988 Phase 1 data at 9th International Calicivirus Conference (Sept 7–11) in Banff.
-
Cocrystal Pharma Q2 2025 net loss narrows to $2.1M; cash at $4.8M; CDI-988 Phase 1 data positive
Q2 2025 net loss of $2.1M ($0.20/share) vs $5.3M ($0.53/share) in Q2 2024, primarily on lower R&D costs.
-
Cocrystal Pharma: Phase 1 CDI-988 well tolerated; Phase 1b planned for norovirus
All CDI-988 doses (100-1200 mg) well tolerated in Phase 1 SAD and MAD cohorts; no severe AEs.
-
Cocrystal to present Phase 1 data for norovirus inhibitor CDI-988 at Calicivirus Conference
CDI-988 is a first-in-class pan-viral protease inhibitor targeting norovirus and coronaviruses.
-
Cocrystal Pharma shareholders elect directors, ratify auditor, approve 2025 equity plan
Elected six directors: Kornberg (4,386,691 for), Frost (4,344,444 for), Hassan (4,440,602 for), Japour, Pfenniger, Rubin.
-
Cocrystal Pharma reduces stockholder meeting quorum to one-third
Board approved bylaw amendment on June 17, 2025 reducing quorum to one-third of voting power.
-
Cocrystal Pharma's norovirus antiviral CDI-988 to be presented at MHSRS in August 2025
CDI-988, a broad-spectrum protease inhibitor, will be featured in an oral presentation at the 2025 Military Health System Research Symposium on August 4, 2025 in Kissimmee, Florida.
-
CC-42344 exhibited EC50 of 0.003 µM against the 2024 Texas H5N1 strain, ~1,000-fold more potent than Tamiflu (EC50 2.69 µM).
-
Net loss for Q1 2025 was $2.3M ($0.23/share) vs $4.0M ($0.39/share) in Q1 2024.
-
CDI-988 demonstrated potent binding to conserved region of GII.17 protease, comparable to activity against GII.4 variants.
-
Cocrystal Pharma furnishes corporate presentation with no material new disclosures
Filed an investor presentation on April 23, 2025 under Item 7.01 Regulation FD.
-
Cocrystal Pharma adopts 2025 Equity Incentive Plan with 1.5M initial shares
Plan effective March 31, 2025; shareholder approval required under Nasdaq rules.
-
Cocrystal Pharma files corrected auditor consent referencing S-3 registration
Corrected Weinberg & Company consent for Form S-3 (No. 333-271883) filed as Exhibit 23.1.
-
Cocrystal Pharma FY2024 net loss $17.5M; cash $9.9M; pipeline advances
Net loss of $17.5M ($1.72 per share) for FY2024, vs. $18.0M ($1.87) in 2023; R&D expenses $12.5M.
-
Filing under Item 7.01 for an investor presentation dated January 13, 2025.
-
Phase 1 MAD study shows CDI-988 well-tolerated up to 800 mg/day for 10 days; new cohort at 1,200 mg for 5 days planned.
-
Cocrystal Pharma extends Phase 2a flu study due to low infection rate, data uninterpretable
No SAEs or drug-related discontinuations in Phase 2a study of oral PB2 inhibitor CC-42344.
-
Cocrystal Pharma Q3 net loss $4.9M; cash $13M; expects topline data from two studies soon
Net loss Q3 2024 of $4.9M ($0.49 per share) vs $4.2M ($0.41) in Q3 2023 which included $1.6M legal settlement.
-
CC-42344 showed in vitro activity against avian influenza A (H5N1) PB2 protein; high-resolution crystal structure confirmed binding.
-
Cocrystal Pharma ratifies exec salary hikes to $416K, $200K bonuses, and RSU grants
James Martin (CFO/co-CEO) and Dr. Sam Lee (President/co-CEO) base salary increased from $400K to $416K, plus $200K bonus and 40,000 RSUs each.
-
Cocrystal Pharma to present at two investor conferences; outlines near-term clinical milestones
Expects to report topline results from influenza A Phase 2a challenge study (CC-42344) in 2024, final report in 2025.
-
Cocrystal Pharma posts Q2 net loss $5.3M, cash $18.1M; pipeline milestones set
Q2 2024 net loss $5.3M ($0.54/sh) vs Q2 2023 net loss $4.2M ($0.41/sh); R&D spend $4.3M up 54% YoY.
-
Cocrystal Pharma reports favorable Phase 1 SAD results for CDI-988 oral pan-viral protease inhibitor
CDI-988 showed favorable safety and tolerability in SAD cohorts; doses from 100 mg to 600 mg.
-
Shareholders approved reducing authorized capital to 100M common + 1M preferred shares; amendment effective June 27, 2024.
-
Cocrystal Pharma reports CC-42344 active against avian H5N1 PB2; Phase 2a results expected H2 2024
In vitro studies show CC-42344 inhibits the PB2 protein of avian influenza A (H5N1) strain from infected dairy cattle.
-
Cocrystal Pharma Q1 net loss $4.0M ($0.39/shr); cash $21.8M; pipeline milestones on track
Net loss improved to $4.0M ($0.39/shr) from $5.2M ($0.64/shr) in Q1 2023.
-
Cocrystal Pharma completes enrollment of 78 subjects in Phase 2a study of CC-42344 for influenza A
Enrolled 78 healthy subjects in randomized, double-blind, placebo-controlled Phase 2a human challenge study of oral PB2 inhibitor CC-42344.
-
Net loss $18.0M ($1.87/share) vs $38.8M ($4.77/share) prior year which included $19.1M goodwill impairment.
-
Cocrystal Pharma gets FDA Pre-IND feedback on oral CC-42344 for influenza A
Received FDA Pre-IND written response to January 2024 submission for oral CC-42344.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.75 · Median 0.55 · Most common event other_material